Antares Pharma (NASDAQ: ATRS) reported Q4 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $14 million versus the consensus estimate of $15.65 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.